linked CD70 to immunosuppression and augmented anti-tumor responses by engineering IL-8 receptor (CXCR1/CXCR2)-modified anti-CD70 CAR-T, leveraging radiation-induced IL-8 release to enhance tumor trafficking (45). This evidence concerns the gene CXCL8 and neoplasm.